Merz North America inked a new licensing agreement with Brickell Biotech, Inc. for the development of a novel retinoid compound for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under this agreement Merz will have an exclusive North American license, with certain additional international rights, to develop and commercialize this compound.
The development of this retinoid product will be a key milestone as Merz Dermatology works to expand its portfolio of treatment options, says the company. In addition, in preclinical studies performed by Brickell, this patent-protected retinoid therapy displayed activity which differentiated it from the topical retinoids currently available on the market.
“We are pleased to be strengthening Merz’s leadership in medical dermatology through targeted development projects such as this licensing agreement with Brickell,” said Greg Besase, vice president and head – US Dermatology for Merz North America. “Merz is proud to affirm its continued commitment to the dermatology space, and we look forward to providing physicians and their patients with a novel treatment option for skin conditions known to be responsive to retinoid therapy.”